Contribution: Industrial Research Assistance Program – Contributions to Firms
MJMG Holdings Inc. O/A Custom Biologics
$307,764.00
Development Rapid Diagnostic Test for COVID-19 (SARS-CoV-2)
FY 2020-21 · 2020-04-01
Summary
DASL RAPIDTM, a molecular diagnostic assay platform, will be used to develop a rapid test for SARS-CoV-2 in fluids collected from throat and nasal swabs. The prototype will be transferable for scale-up in public health laboratories or point-of-care systems.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
867782351
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 1 | 2020-04-01 | 2020-21 | $307,764.00 |
| 2 | 2020-04-01 | 2020-21 | $307,764.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 92 jours.
Agreement End Date
2021-05-31
Agreement Number
947650
Agreement Start Date
2020-04-01
Agreement Title
Development Rapid Diagnostic Test for COVID-19 (SARS-CoV-2)
Agreement Title (French)
Développement d'un test de diagnostic rapide pour la COVID-19 (SRAS-CoV-2)
Agreement Type
Contribution
Agreement Value
$307,764.00
Amendment Date
2021-02-11
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
DASL RAPIDTM, a molecular diagnostic assay platform, will be used to develop a rapid test for SARS-CoV-2 in fluids collected from throat and nasal swabs. The prototype will be transferable for scale-up in public health laboratories or point-of-care systems.
Description (French)
DASL RAPIDTM, une plateforme de test de diagnostic moléculaire, sera utilisée pour développer un test rapide pour le SRAS-CoV-2 dans les fluides collectés à partir de prélèvements dans la gorge et le nez. Le prototype sera transférable pour une mise à l'échelle dans les laboratoires de santé publique ou les systèmes de prise en charge.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Etobicoke North
Federal Riding (French)
Etobicoke-Nord
Federal Riding Number
35029
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
867782351
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
MJMG Holdings Inc. O/A Custom Biologics
Recipient Operating Name
Custom Biologics
Recipient Postal Code
M9W 4Z4
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2020-2021-Q1-947650
